'Trump's drug price cut plan may trigger global repricing, pressure on India'

The US move could push prices in lower-cost countries like India as manufacturers would seek to recover losses and R&D costs from these nations. 

"It is likely to trigger a global price recalibration, with pharmaceutical giants intensifying pressure on lower-cost markets like India to raise their prices by tightening patent laws through trade negotiations," Global Trade Research Initiative (GTRI) GTRI Founder Ajay Srivastava said on Monday. Trump's MFN (most-favoured nation) pricing policy should be a wake-up call, as pharmaceutical companies face tighter price controls in the West, they will redouble their efforts to raise prices in markets like India, he said.

"The battleground is no longer just legal, it has moved to trade negotiations. India must respond with strategic clarity and unyielding resolve," he added.